Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$75,985.00+0.47%ETH$2,402.74+0.14%GOLD$4,302.50-0.70%OIL$102.02-3.60%
Smart Investors Daily
SR

NASDAQ · SRPT

Sarepta Therapeutics, Inc.

Healthcare · Biotechnology

$20.72

Down-$0.96 (-4.63%)

Updated Sep 16, 2026, 9:44 PM

SID Score

6.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.13B
P/E ratio
-7.89
Dividend yield
0.00%
52-week range
$14.68 – $23.85
Volume
2.53M
Avg. volume
5.43M

Price performance

SRPT price history

1M range · 20 trading sessions · Daily adjusted prices

SRPT closed at $20.72 after 20 trading sessions, up 14.98% for the selected period.

Last close
$20.72
Period change
+14.98%
Period low
$18.02
Period high
$23.21
Daily close
View OHLC price history
SRPT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$20.81$21.06$20.29$20.722.53M
Sep 14, 2026$20.55$21.40$20.38$20.922.19M
Sep 11, 2026$20.76$21.10$20.29$20.451.81M
Sep 10, 2026$22.02$22.02$20.28$20.522.2M
Sep 9, 2026$20.805$23.22$20.63$22.024.17M
Sep 8, 2026$19.86$21.32$19.51$20.946.24M
Sep 4, 2026$22.58$22.645$21.98$22.502.96M
Sep 3, 2026$23.15$23.34$22.42$22.992.77M
Sep 2, 2026$21.33$23.62$21.33$23.214.81M
Sep 1, 2026$20.88$21.82$20.5451$21.332.62M
Aug 31, 2026$20.56$21.16$20.1821$21.032.66M
Aug 28, 2026$21.49$22.58$20.83$20.863.61M
Aug 27, 2026$19.35$22.59$18.77$21.597.92M
Aug 26, 2026$18.74$19.48$18.31$19.462.41M
Aug 25, 2026$18.42$19.045$18.19$18.921.7M
Aug 24, 2026$18.53$18.705$17.90$18.131.38M
Aug 21, 2026$19.39$19.73$18.66$18.791.67M
Aug 20, 2026$19.42$19.95$18.59$19.222.91M
Aug 19, 2026$18.74$20.19$18.74$19.734.94M
Aug 18, 2026$18.17$18.29$17.875$18.021.6M

Latest SRPT news

The latest Smart Investors Daily articles mentioning SRPT.

Stock researchCompany · Overview

SRPT research

Overview

Company profile and research snapshot.

Company profile

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$25.92
Implied upside
—
Analysts
—
SRPT recent ratings
DateFirmRatingTarget
Jul 9, 2026Piper SandlerNeutral—
Jul 9, 2026Wolfe ResearchOutperform—
Apr 16, 2026HC Wainwright & Co.Sell—
Mar 26, 2026CitigroupSell—
Mar 26, 2026NeedhamUnderperform—
Open full forecast

News briefing

Generated Sep 16, 2026, 7:23 PM

Why Is SRPT Down Today?

Sarepta Therapeutics shares declined 4.21% today as the market digests recent company presentations and pipeline updates. While the biotech firm is making progress on key programs, investor sentiment appears cautious as the company navigates commercialization challenges and upcoming clinical readouts.

    Bottom line: SRPT's 4.21% decline reflects a market pause as investors await the FSHD and DM1 readouts while assessing ELEVIDYS's stabilizing demand trajectory. The near-term risk/reward hinges on clinical trial success in muscular dystrophies, while longer-term growth prospects remain supported by favorable market dynamics in oligonucleotide therapeutics. Investors should monitor upcoming data readouts and quarterly commercial updates closely.

    Yahoo · Sep 15, 2026

    Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

    Oligonucleotide Therapeutics Expand Beyond Rare Diseases as RNA Innovation, Targeted Delivery and Patient-Friendly Dosing Accelerate AdoptionDublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Oligonucleotide Therapeutics Market to Reach USD 72.1 Billion by 2035 at a 23.4% CAGR The global oligonucleotide therapeutics market was valu

    Yahoo · Sep 15, 2026

    Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

    Sarepta Therapeutics (NASDAQ:SRPT) outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat. Chie

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By